Literature DB >> 27189927

"Pseudoprogression" of Pulmonary Pleomorphic Carcinoma during Nivolumab Therapy.

Kentaro Ito1, Osamu Hataji1, Koji Katsuta2, Tetsu Kobayashi3, Esteban C Gabazza4, Yasushi Yatabe5, Osamu Taguchi6, Nobuyuki Yamamoto7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27189927     DOI： 10.1016/j.jtho.2016.05.002

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  11 in total

1.  Combination of Pembrolizumab With Platinum-containing Chemotherapy for Pleomorphic Carcinoma of the Lung.

Authors:  Shinichiro Okauchi; Yuika Sasatani; Toshihiro Shiozawa; Hideyasu Yamada; Kunihiko Miyazaki; Norio Takayashiki; Hiroaki Satoh
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

2.  Paradoxical response to osimertinib therapy in a patient with T790M-mutated lung adenocarcinoma.

Authors:  Shinichiro Okauchi; Hajime Osawa; Kunihiko Miyazaki; Mio Kawaguchi; Hiroaki Satoh
Journal:  Mol Clin Oncol       Date:  2017-10-27

3.  Expectoration of tonsillar metastasis of pulmonary pleomorphic carcinoma after pseudoprogression: A case report.

Authors:  Tomoki Kuge; Fukuko Okabe; Yuji Yamamoto; Mikako Ishijima; Takeshi Uenami; Masaki Kanazu; Yuki Akazawa; Yukihiro Yano; Toshihiko Yamaguchi; Masahide Mori
Journal:  Thorac Cancer       Date:  2021-05-11       Impact factor: 3.500

4.  Pulmonary pleomorphic carcinoma with few PD-1-positive immune cells and regulatory T cells that showed a complete response to nivolumab.

Authors:  Kazuaki Okamura; Yuichi Fukuda; Hiroshi Soda; Daiki Ogawara; Keisuke Iwasaki; Shinichiro Fuchi; Takayuki Suyama; Masataka Yoshida; Tatsuhiko Harada; Minoru Fukuda; Hiroshi Mukae
Journal:  Thorac Cancer       Date:  2017-11-13       Impact factor: 3.500

5.  Pulmonary pleomorphic carcinoma with pseudoprogression during nivolumab therapy and the usefulness of tumor markers: A case report.

Authors:  Akihiro Yoshimura; Chieko Takumi; Taisuke Tsuji; Ryosuke Hamashima; Shinsuke Shiotsu; Tatsuya Yuba; Yoji Urata; Noriya Hiraoka
Journal:  Clin Case Rep       Date:  2018-05-29

6.  Dramatic response to nivolumab after local radiotherapy in pulmonary pleomorphic carcinoma with rapid progressive post-surgical recurrence.

Authors:  Daizo Yaguchi; Motoshi Ichikawa; Masao Ito; Sawako Okamoto; Hayata Kimura; Kazuko Watanabe
Journal:  Thorac Cancer       Date:  2019-03-12       Impact factor: 3.500

7.  A Histologically Complete Response to Immunotherapy Using Pembrolizumab in a Patient with Giant Cell Carcinoma of the Lung: An Additional Report and Literature Review.

Authors:  Tomoo Kakimoto; Mamoru Sasaki; Tatsuya Yamamoto; Arifumi Iwamaru; Kentaro Ogata; Ko Lee; Shingo Nakayama; Naoto Minematsu
Journal:  Case Rep Oncol Med       Date:  2019-10-15

8.  Pulmonary Pleomorphic Carcinoma Mimicking Primary Sarcoma of the Neck: A Case Report and Literature Review.

Authors:  Daishi Ogawa; Masahisa Arahata; Masato Kuriyama; Shunji Shinagawa; Gakuto Tomizawa; Yukihiro Shimizu
Journal:  Clin Interv Aging       Date:  2021-02-23       Impact factor: 4.458

9.  Pulmonary large cell carcinoma, highly positive for PD-L1, shows marked response to pembrolizumab: A case report.

Authors:  Naoyuki Okabe; Hayato Mine; Hironori Takagi; Masayuki Watanabe; Satoshi Muto; Yuki Matsumura; Yutaka Shio; Hiroyuki Suzuki
Journal:  Thorac Cancer       Date:  2021-02-19       Impact factor: 3.500

10.  Case series of pleomorphic carcinomas of the lung treated with nivolumab.

Authors:  Masaki Kanazu; Takeshi Uenami; Yukihiro Yano; Saeko Nakatsubo; Yuki Hosono; Mikako Ishijima; Yuki Akazawa; Toshihiko Yamaguchi; Koji Urasaki; Masahide Mori; Soichiro Yokota
Journal:  Thorac Cancer       Date:  2017-09-07       Impact factor: 3.500
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.